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Long-term prognosisBACKGROUND: Maximal doses of potent statins are the basement of treatment of familial hyper-
cholesterolemia (FH). Little is known about the use of different statin regimens in FH.
OBJECTIVES: The objectives of the study were to describe the treatment changes and low-density
lipoprotein cholesterol (LDL-C) goal achievement with atorvastatin (ATV) and rosuvastatin (RV) in the
SAFEHEART cohort, as well as to analyze the incidence of atherosclerotic cardiovascular events
(ACVEs) and changes in the cardiovascular risk.
METHODS: SAFEHEART is a prospective follow-up nationwide cohort study in a molecularly
defined FH population. The patients were contacted on a yearly basis to obtain relevant changes in
life habits, medication, and ACVEs.
RESULTS: A total of 1939 patients were analyzed. Median follow-up was 6.6 years (5–10). The
estimated 10-year risk according the SAFEHEART risk equation was 1.61 (0.67–3.39) and 1.22
(0.54–2.93) at enrollment for ATV and RV, respectively (P , .001). There were no significant differ-
ences at the follow-up: 1.29 (0.54–2.82) and 1.22 (0.54–2.76) in the ATV and RV groups, respectively
(P 5 .51). Sixteen percent of patients in primary prevention with ATV and 18% with RV achieved an
LDL-C ,100 mg/dL and 4% in secondary prevention with ATV and 5% with RV achieved an LDL-C
,70 mg/dL. The use of ezetimibe was marginally greater in the RV group. One hundred sixty ACVEs
occurred during follow-up, being its incidence rate 1.1 events/100 patient-years in the ATV group and
1.2 in the RV group (P 5 .58).
CONCLUSION: ATV and RV are 2 high-potency statins widely used in FH. Although the reduction
in LDL-C levels was greater with RV than with ATV, the superiority of RV for reducing ACVEs was
not demonstrated.
 2019 National Lipid Association. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Heterozygous familial hypercholesterolemia (FH) is a
codominant autosomal disorder with a prevalence around
1:250 cases worldwide, making it by far the most common
genetic condition causing premature morbidity and mor-
tality from atherosclerotic cardiovascular disease.1
Although lipid-lowering therapy (LLT) has shown a reduc-
tion in coronary and total mortality in patients with FH and
LLT has improved in recent years, most patients with FH
do not reach an optimal therapeutic level of low-density li-
poprotein cholesterol (LDL-C) and, therefore, continue to
have a high risk of premature atherosclerotic cardiovascular
events (ACVEs).2–4
Little is known about the use of different statins and the
achievement of LDL-C goals in patients with FH. National
registries are a valuable source to provide this key infor-
mation, necessary to improve models of health care, family
cascade screening, the education of physicians and patients,
and to help define priorities in therapeutic guidelines andhealth planning policies.5,6 The SAFEHEART study (Span-
ish Familial Hypercholesterolemia Cohort Study), a na-
tional registry of patients with FH was designed to
improve the knowledge of this disease in Spain.7,8
The objective of this study was to describe the changes
in the treatment and achievement of LDL-C goals with
potent statins such as atorvastatin (ATV) and rosuvastatin
(RV) used alone or in combination with Ezetimibe in the
SAFEHEART cohort from inclusion until the last follow-
up, as well as to analyze the incidence of cardiovascular
events and changes in the estimated risk in the FH
population treated with 2 intensive statin regimens.Methods
Design and population
SAFEHEART is a prospective nationwide cohort study,
open, multicentric with long-term protocolized follow-up in
Perez de Isla et al Atorvastatin versus rosuvastatin in FH 991a molecularly defined FH population with participation
from primary and specialized care.7 The recruitment of
families with FH began in 2004 and the end date for report-
ing events was January 2019. This study was approved by
the ethics committee of the Fundacion Jimenez Dıaz Hos-
pital in Madrid and all the subjects gave their written
informed consent. The objectives of treatment were defined
according to the hyperlipidemia guidelines.9 These guide-
lines were used to inform, educate, and train participating
physicians and include patients and families in this registry.
The coordinating center of the SAFEHEART study
managed the follow-up of the patients. The patients were
contacted on a yearly basis by using a standardized
telephone survey to obtain relevant changes in life habits,
medication, and the appearance of cardiovascular events.
The definitions of previous and incident ACVEs have been
previously reported.10
Variables
In addition to the aforementioned demographic and
clinical variables, age, classic cardiovascular risk factors,
physical examination, and LLT were included. The lipid
profiles were determined in venous blood samples in a
centralized laboratory.7 The serum concentration of LDL-C
was calculated using the Friedewald formula. The DNA
was isolated from whole blood using standard methods,
and the genetic diagnosis of FH was performed as previ-
ously described.11 Cardiovascular risk was defined by the
SAFEHEART risk equation (SAFEHEART-RE).10 The
classification of LLT was defined as previously reported4:
maximal statin dose as ATV 40 to 80 mg/d or RV 20 to
40 mg/d which was considered high-intensity statin doses;
maximal combined therapy as maximal statin dose plus
ezetimibe 10 mg/d; and maximal LLT as any LLT expected
to produce at least a 50% reduction in LDL-C baseline
levels. The classification of LLT intensity, in terms of po-
tency, has been previously reported.12,13
Incident ACVEs during follow-up was defined as the
occurrence after enrollment of the first one of the
following: fatal or nonfatal myocardial infarction, fatal or
nonfatal ischemic stroke, coronary revascularization, pe-
ripheral artery revascularization, and cardiovascular death
(any death related to cardiovascular disease or derived of
cardiovascular therapeutic procedures not described in the
previous definitions).
Statistical analysis
The statistical analysis was carried out with the STATA
program, version 12.0 (Stata Corporation, College Station,
TX). A descriptive analysis was carried out to report the
number of cases and percentages for the qualitative vari-
ables, the mean, and the standard deviation for the
quantitative variables that followed a normal distribution
and the median and interquartile range for the quantitative
variables that did not follow a normal distribution.Comparisons of proportions between the qualitative vari-
ables were carried out using the chi square test and the
binomial test to compare the proportion observed in each
treatment group with the value of the total population. The
mean comparisons of the quantitative variables were
analyzed with the Student’s t-test for independent data,
and the medians comparisons were analyzed with the
Mann-Whitney U-test for independent data. The incidence
rate of cardiovascular events was calculated as the quotient
in which the numerator is the number of observed events
and the denominator is the time at risk for the event. The
time at risk was the sum of the follow-up time of patients
who do not have an event plus the sum of the time until
the event appears in the patients in which the event occurs.
The incidence rate was expressed as the number of events
per 100 patient-years. A value of P , .05 was considered
statistically significant.Results
A total of 4870 subjects were enrolled, 3601 with
genetic diagnosis of FH and 1269 nonaffected relatives.
The analysis in this study was made with 1939 patients with
FH, after excluding homozygous subjects, younger than
18 years, without complete follow-up, those who did not
receive LLT at the last follow-up, took a statin different
from ATV or RV, or were in treatment with inhibitors of
proprotein convertase subtilisin/kexin type 9 (PCSK9)
(Fig. 1). The median follow-up time was 6.6 years (5–
10 years). Three hundred patients changed during the
follow-up from ATV to RV and 46 patients from RV to
ATV. All of them were treated with the last drug until the
last contact and always, continuously, for more than half
of the follow-up.
The main characteristics of the cohort are described in
Table 1. It is interesting to point out that only statistically
significant differences were found between the ATV group
and the RV group in the following variables: use of statins
at maximum dose (71% and 81% in the ATV and RV
groups, respectively, P , .001), use of added ezetimibe
(65% and 77% in the ATV and RV groups, respectively,
P , .001), use of maximum combined treatment (53%
and 66% in the ATV and RV groups, respectively,
P , .001), and maximum LLT (88% and 81% in the
ATV and RV groups, respectively, P , .001). Likewise,
505 patients in the ATV group (47%) and 252 in the RV
group (29%) were managed in primary care (P , .001).
Regarding the lipid parameters, statistically significant dif-
ferences were found in LDL-C levels [128 mg/dL (107–
152) and 123 mg/dL (104–146) in the ATV and RV groups,
respectively; P , .005] and TG levels [82 mg/dL (64–116)
and 93 mg/dL (70–129) in the ATV and RV groups, respec-
tively; P , .001].
Figure 2 shows the evolution between the time of enroll-
ment in the SAFEHEART study and the time of the last
follow-up in the ATVor RV treatment in the studied cohort.
992 Journal of Clinical Lipidology, Vol 13, No 6, December 2019It is important to highlight the considerable change that all
monotherapies and combined therapies have undergone,
highlighting the very important numerical increase of pa-
tients treated with coadministration of RV and ezetimibe:
200 patients at the time of enrollment (10%) and 675 pa-
tients at the time of the last follow-up (35%) (P , .001).
Table 2 shows the potency of lipid-lowering treatment
used at inclusion and at the time of the last follow-up in
the ATV and RV groups expressed in potency terms.
Although the potency of the treatment in this population
did not strictly follow a normal distribution and, therefore,
was expressed as a median, values are given here as means
because it may be more informative. In both groups, theFigure 1 Flow diagram showing the recruitment of cases in the SAFE
lowering therapy; PCSK9, proprotein convertase subtilisin/kexin type 9
hypercholesterolaemia; HoFH, homozygous familiar hypercholesterolaepotency increased during the follow-up, going from
6.7 6 1.6 to 7.1 6 1.4 in the ATV group (P , .001) and
from 6.9 6 1.4 to 7.5 6 1.2 in the RV group (P , .001).
Regarding the risk of developing a cardiovascular event
estimated by the SAFEHEART-RE, Table 3 shows how in
the inclusion, the estimated 10-year risk was 1.61 (0.67–
3.39) and 1.22 (0.54–2.93) in the groups ATV and RV,
respectively (P , .001), meaning there were no significant
differences between the 2 groups at the time of the last
follow-up: 1.29 (0.54–2.82) and 1.22 (0.54–2.76) in the
ATV and RV groups, respectively (P 5 .51).
Regarding the achievement of LDL-C goals, 16% of
patients in primary prevention in the ATV group and 18%HEART registry. ATV, atorvastatin; RV, rosuvastatin; LLT, lipid-
; FH, familial hypercholesterolemia; HeFH, heterozygous familiar
mia.
Table 1 Characteristics of the SAFEHEART population treated with ATV or RV in the last follow-up
Qualitative variables; n (%) Total ATV RV P
n 1939 1065 874 ,.001
Gender (male) 890 508 (48) 382 (44) .08
ACVEs at enrollment 232 134 (13) 98 (11) .35
Nonfatal ACVEs in follow-up 128 61 (6) 67 (8) .09
Fatal ACVEs in follow-up 42 28 (3) 14 (2) .12
Fatal or nonfatal ACVEs in follow-up 160 83 (8) 77 (9) .42
ACVEs at enrollment or during follow-up 311 168 (16) 143 (16) .73
Diabetes mellitus 160 93 (9) 67 (8) .39
Hypertension 432 237 (22) 195 (22) .97
Active smoking 291 160 (15) 131 (15) .98
Maximal statin dose 1460 755 (71) 705 (81) ,.001
Ezetimibe 1367 692 (65) 675 (77) ,.001
Maximal combined therapy 1135 561 (53) 574 (66) ,.001
Maximum lipid-lowering therapy 1647 942 (88) 705 (81) ,.001
Patients in primary prevention 1628 897 (84) 731 (84) .7
Patients in secondary prevention 281 148 (14) 133 (15) .5
LDL-C,100 mg/dL in patients in primary prevention 274 140 (16) 134 (18) .14
LDL-C,70 mg/dL in patients in secondary prevention 13 6 (4) 7 (5) .56
Patients managed in primary care 757 505 (47) 252 (29) ,.001
Quantitative variables; median (IQR)
Age (y) 54 (42–65) 54 (42–66) 54 (43–65) .70
BMI Kg/m2 25.8 (23–29) 25.7 (23–28) 26.1 (23–29) .07
Total cholesterol mg/dL 198 (176–225) 200 (177–227) 197 (176–222) .12
LDL-C mg/dL 125 (106–148) 128 (107–152) 123 (104–146) ,.005
HDL-C mg/dL 51 (43–61) 51 (43–61) 51 (44–60) .95
TG mg/dL 86 (67–121) 82 (64–116) 93 (70–129) ,.001
Years on statin treatment 18 (13–26) 18 (13–26) 18 (13–26) .71
Years on Ezetimibe treatment* 4.7 (0–11) 5.7 (0–12) 3.8 (0–11) .08
ATV, atorvastatin; RV, rosuvastatin; ACVEs, atherosclerotic cardiovascular events; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density
lipoprotein cholesterol; TG, triglycerides; IQR, interquartile range.
*Only patients on ezetimibe treatment.
Perez de Isla et al Atorvastatin versus rosuvastatin in FH 993in the RV group achieved an LDL-C ,100 mg/dL and 4%
in secondary prevention in the ATV group and 5% in the
RV group achieved an LDL-C ,70 mg/dL. Figure 3 showsFigure 2 Changes in the treatment with ATV or RV in the
SAFEHEART registry. ATV, atorvastatin; EZ, ezetimibe; RV, ro-
suvastatin; Tot, total.the achievement of objectives in LDL-C. Nevertheless,
there was an increase during follow-up in the percentage
of subjects without ACVEs who reached an LDL-C under
115 and 130 mg/dL, respectively, and the increase was sig-
nificant in the RV group compared with the ATV group
(P , .05).
During follow-up, a total of 160 fatal or nonfatal first
incident ACVEs were recorded; 128 first nonfatal events
and 42 deadly events (Table 1). The overall incidence rate
of cardiovascular events was 1.15 events/100 patient-years;
1.1 in the ATV group and 1.2 in the RV group (P 5 .58).
Figure 4 shows the survival curves in both treatment groups
for incident ACVEs.
Discussion
This study is the first, to our knowledge, to compare the
use in real clinical practice of 2 high-potency statins in
patients with FH. It is a prospective long-term follow-up
study analyzing the incidence of fatal and nonfatal
cardiovascular events. It is well known that lipid-lowering
treatment with high-potency statins in FH lowers LDL-C
Table 2 Classification of lipid-lowering treatment by
potency* (mean 6 SD)
Potency Total ATV RV P
Potency at
enrollment
6.8 6 1.5 6.7 6 1.6 7.1 6 1.4 ,.001
Potency at
follow-up
7.2 6 1.4 6.9 6 1.4 7.5 6 1.2 ,.001
ATV, atorvastatin group; RV, rosuvastatin group.
*Lipid-lowering therapy potency has been calculated according the
method described in the study by Penning-van Beest et al12 modified
by Masana et al.13 As a reference point, the potency of atorvastatin
40 mg is 6.
994 Journal of Clinical Lipidology, Vol 13, No 6, December 2019levels, a fact that is associated with a reduction in the
incidence of cardiovascular events.14 A strong recommen-
dation for the use of high-intensity statins15 and combined
therapy with ezetimibe should be established in patients
with FH,16 with the use of ezetimibe now being well sup-
ported by IMPROVE-IT.17 As the results of the present
study show, although the reduction in LDL-C levels is
greater in the group treated with RV than in the group
treated with ATV, the incidence of fatal and nonfatal car-
diovascular events is similar in both groups.
In parallel with the findings of a study comparing the
efficacy of both statins to reduce the progression of
coronary atherosclerosis18 and in which no significant dif-
ferences were found between the 2 drugs, no differences
were found in the present study when the incidence rate
of cardiovascular events was analyzed. It is well known
that the burden of coronary atherosclerosis is directly and
proportionately related to the incidence of cardiovascular
events, including coronary events.19 This parallelism be-
tween the burden of atherosclerosis and cardiovascular
events reinforces the plausibility of the findings of our
study, which align with the findings of the aforementioned
study. However, another recent study shows that although
RV and ATV at doses of 10 and 20 mg, respectively, ob-
tained similar reductions in LDL-C levels, RV showed
that it was able to improve earlier and more robustly than
ATV the image parameters related to the stability of the
atherosclerosis plaques. Nevertheless, both statins signifi-
cantly reduced the atheroma volume.20 Statins, in additionTable 3 Ten-year cardiovascular risk in the SAFEHEART cohort with
Risk Total ATV
Ten-year SAFEHEART-
RE risk at enrollment
1.54 (0.64–3.39) 1.6
Ten-year SAFEHEART-
RE risk at follow-up
1.27 (0.54–2.76) 1.2
ATV, atorvastatin group; RV, rosuvastatin group; SAFEHEART-RE, SAFEHEAR
Median (IQR).to their lipid-lowering potency, have several effects inde-
pendent of their lipid-lowering effect, the so-called pleio-
tropic effects.21 One of these pleiotropic effects is its
ability to stabilize atherosclerosis plaques, thus preventing
its rupture and the appearance of subsequent cardiovascular
events. Most acute coronary syndromes are secondary to
the rupture of vulnerable atherosclerotic plaques. After
the instabilization of an atherosclerotic plaque, a process
of healing or stabilization arises. However, until this study,
it was not known if there are statins that favor more than
others this stabilization of the atherosclerotic plaque.
It is important to emphasize that although more than
80% patients analyzed in our study were on maximum LLT,
the majority did not achieve the recommended LDL-C
goals. These findings show the difficulty in reducing the
LDL-C in patients with FH as they usually have high
baseline LDL-C levels.16,22 However, although the targets
are not fully achieved in many patients, we can affirm
that their control has improved with respect to previous
data from the same cohort.4 These results depict that a
considerable number of patients with FH may be candidates
to receive new medications, such as PCSK9 inhibitors.
With reference to this aspect, we have recently shown
that the application of SAFEHEART-RE can help make a
better selection of patients with FH for the use of PCSK9
inhibitors to improve the cost-effectiveness of its use.23
Effective lipid-lowering therapies with statins and
ezetimibe are now available as generic medications. A
point of special consideration is that RV was marketed in
September 2009 (ATV in October 1997) in Spain and
therefore takes longer to be available as generic. Despite
this delay in its availability, we can observe that the use of
RV has increased considerably in patients with FH,
especially in those who are managed in the specialized
health care system. Furthermore, a recent study concerning
cost-effectiveness of LLT in patients with FH involved in a
national detection program has shown that the use of ATV
and RV with or without ezetimibe is cost-effective.24
When applying the SAFEHEART-RE equation to the
patients analyzed at the time of their enrollment in the
SAFEHEART registry and at the time of the last follow-up,
no significant differences were found in the estimated risk
reduction between these 2 moments between the group that
used ATV and the group that used RV.ATV/RV
RV P
1 (0.67–3.39) 1.22 (0.54–2.93) ,.001
9 (0.54–2.82) 1.22 (0.54–2.76) .51
T risk equation; IQR, interquartile range.
Figure 3 Goal achievement for different LDL cholesterol thresholds in FH patients with and without atherosclerotic cardiovascular dis-
ease in the atorvastatin and rosuvastatin groups. CVD (1): Patient who had a history of atherosclerotic cardiovascular disease; CVD (2):
patient without history of atherosclerotic cardiovascular disease. LDL-C, low-density lipoprotein cholesterol; FH, familial hypercholester-
olemia; CVD, cardiovascular disease.
Perez de Isla et al Atorvastatin versus rosuvastatin in FH 995The strengths and limitations of our study merit to be
taken into account. The SAFEHEART study is a nation-
wide, long-term prospective contemporary cohort of a
molecularly defined FH population. This fact makes these
results as a reference because of the lack of other cohorts of
similar characteristics and similar follow-up around the
world. Nevertheless, the 2 groups considered for this study
were not randomly assigned. Furthermore, RV was the
newer drug pointed out and, although known risk factors
were matched, an important limitation is that RV might
have been favored for patients perceived by physicians toFigure 4 Survival curves for incident ACVEs in both treatment
groups. ACVEs, atherosclerotic cardiovascular events.be at higher risk. This fact could be reflected in the greater
use of RV in referral practice as compared to primary care.
Another major limitation is the very small differences in
LDL-C level and in risk of ACVEs between the ATV and
RV groups that raise the possibility that unaccounted
confounders and limited statistical power could explain
the lack of differences in ACVEs.Conclusion
ATV and RV are 2 high-potency statins widely used for
patients with FH. The results of the present study show that
although the reduction in LDL-C levels was greater in the
group treated with RV than in the group treated with ATV,
the superiority of RV for reducing ACVEs was not
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